Elevated levels of high-sensitivity C-reactive protein are associated with mild cognitive impairment and its subtypes: Results of a population-based case-control study

Journal of Alzheimer's Disease

Volumn 28, Issue 3, 2012, Pages 503-514

  Dlugaj, Martha ^a   Gerwig, Marcus ^a   Wege, Natalia ^b   Siegrist, Johannes ^b   Mann, Klaus ^a   Bröcker Preuß, Martina ^a   Dragano, Nico ^a   Moebus, Susanne ^a   Jöckel, Karl Heinz ^a   Bokhof, Beate ^a   Möhlenkamp, Stefan ^a   Erbel, Raimund ^a   Weimar, Christian ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Case control study; high sensitivity C reactive protein (hsCRP); inflammation; mild cognitive impairment (MCI)

Indexed keywords

APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; C REACTIVE PROTEIN; CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROPSYCHOLOGICAL TEST; POPULATION BASED CASE CONTROL STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY;

EID: 84858038444     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-111352     Document Type: Article

References (63)

1. Alonso A, Jacobs DR Jr, Menotti A, Nissinen A, Dontas A, Kafatos A, Kromhout D (2009) Cardiovascular risk factors and dementia mortality: 40 years of follow-up in the Seven Countries Study. J Neurol Sci 280, 79-83.
2. Gorelick PB (2005) William M. Feinberg lecture: Cognitive vitality and the role of stroke and cardiovascular disease risk factors. Stroke 36, 875-879.
3. Schmidt R, Schmidt H, Curb JD, Masaki K, White LR, Launer LJ (2002) Early inflammation and dementia: A 25- year follow-up of the Honolulu-Asia aging study. Ann Neurol 52, 168-174. (Pubitemid 34810596)
4. Tan ZS, Beiser AS, Vasan RS, Roubenoff R, Dinarello CA, Harris TB, Benjamin EJ, Au R, Kiel DP, Wolf PA, Seshadri S (2007) Inflammatory markers and the risk of Alzheimer disease: The Framingham Study. Neurology 68, 1902-1908. (Pubitemid 46848622)
5. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511. (Pubitemid 36158056)
6. Marioni RE, Stewart MC, Murray GD, Deary IJ, Fowkes FG, Lowe GD, Rumley A, Price JF (2009) Peripheral levels of fibrinogen, C-reactive protein, and plasma viscosity predict future cognitive decline in individuals without dementia. Psychosom Med 71, 901-906.
7. Yaffe K, Kanaya A, Lindquist K, Simonsick EM, Harris T, Shorr RI, Tylavsky FA, Newman AB (2004) The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292, 2237-2242. (Pubitemid 39473161)
8. Xu G, Zhou Z, Zhu W, Fan X, Liu X (2009) Plasma C-reactive protein is related to cognitive deterioration and dementia in patients with mild cognitive impairment. J Neurol Sci 284, 77-80.
9. Bettcher BM, Wilheim R, Rigby T, Green R, Miller JW, Racine CA, Yaffe K, Miller BL, Kramer JH (2011) C-reactive protein is related to memory and medial temporal brain volume in older adults. Brain Behav Immun, doi:10.1016/j.bbi. 2011.07.240.
10. van den Kommer TN, Dik MG, Comijs HC, Jonker C, Deeg DJ (2010) The role of lipoproteins and inflammation in cognitive decline: Do they interact? Neurobiol Aging, doi:10.1016/j.neurobiolaging.2010.05.024.
11. Schram MT, Euser SM, de Craen AJ, Witteman JC, Frolich M, Hofman A, Jolles J, Breteler MM, Westendorp RG (2007) Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 55, 708-716. (Pubitemid 46668977)
12. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenberg A, van Swieten JC, Stijnen T, Hofman A, Witteman JC, Breteler MM (2004) Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch Neurol 61, 668-672. (Pubitemid 38637682)
13. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F (2005) Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: Systematic review and meta-analysis. Lancet Neurol 4, 371- 380.
14. Marchesi VT (2011) Alzheimer's dementia begins as a disease of small blood vessels, damaged by oxidative-induced inflammation and dysregulated amyloid metabolism: Implications for early detection and therapy. FASEB J 25, 5-13.
15. Lin HB, Yang XM, Li TJ, Cheng YF, Zhang HT, Xu JP (2009) Memory deficits and neurochemical changes induced by C-reactive protein in rats: Implication in Alzheimer's disease. Psychopharmacology (Berl) 204, 705-714.
16. Heneka MT, O'Banion MK, Terwel D, Kummer MP (2010) Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 117, 919-947.
17. Mielke MM, Zandi PP, Shao H, Waern M, Ostling S, Guo X, Bjorkelund C, Lissner L, Skoog I, Gustafson DR (2010) The 32-year relationship between cholesterol and dementia from midlife to late life. Neurology 75, 1888-1895.
18. Rusanen M, Kivipelto M, Quesenberry CP Jr, Zhou J, Whitmer RA (2011) Heavy smoking in midlife and long-term risk of Alzheimer disease and vascular dementia. Arch Intern Med 171, 333-339.
19. Laurin D, David Curb J, Masaki KH, White LR, Launer LJ (2009) Midlife C-reactive protein and risk of cognitive decline: A 31-year follow-up. Neurobiol Aging 30, 1724- 1727.
20. Vlad SC, Miller DR, Kowall NW, Felson DT (2008) Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 70, 1672-1677. (Pubitemid 351644133)
21. McGeer PL, McGeer EG (2007) NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 28, 639-647. (Pubitemid 46349357)
22. Jonker C, Comijs HC, Smit JH (2003) Does aspirin or other NSAIDs reduce the risk of cognitive decline in elderly persons? Results from a population-based study. Neurobiol Aging 24, 583-588. (Pubitemid 36513706)
23. Trollor JN, Smith E, Baune BT, Kochan NA, Campbell L, Samaras K, Crawford J, Brodaty H, Sachdev P (2010) Systemic inflammation is associated with MCI and its subtypes: The Sydney Memory and Aging Study. Dement Geriatr Cogn Disord 30, 569-578.
24. Roberts RO, Geda YE, Knopman DS, Boeve BF, Christianson TJ, Pankratz VS, Kullo IJ, Tangalos EG, Ivnik RJ, Petersen RC (2009) Association of C-reactive protein with mild cognitive impairment. Alzheimers Dement 5, 398-405.
25. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
26. Schmermund A, Mohlenkamp S, Stang A, Gronemeyer D, Seibel R, Hirche H, Mann K, Siffert W, Lauterbach K, Siegrist J, Jockel KH, Erbel R (2002) Assessment of clinically silent atherosclerotic disease and established and novel risk factors for predicting myocardial infarction and cardiac death in healthy middle-aged subjects: Rationale and design of the Heinz Nixdorf RECALL Study. Risk Factors, Evaluation of Coronary Calcium and Lifestyle. Am Heart J 144, 212-218. (Pubitemid 34879641)
27. Stang A, Moebus S, Dragano N, Beck EM, Mohlenkamp S, Schmermund A, Siegrist J, Erbel R, Jockel KH (2005) Baseline recruitment and analyses of nonresponse of the Heinz Nixdorf Recall Study: Identifiability of phone numbers as the major determinant of response. Eur J Epidemiol 20, 489-496. (Pubitemid 40933925)
28. Dlugaj M, Weimar C, Wege N, Verde PE, Gerwig M, Dragano N, Moebus S, Jockel KH, Erbel R, Siegrist J (2010) Prevalence of mild cognitive impairment and its subtypes in the Heinz Nixdorf Recall study cohort. Dement Geriatr Cogn Disord 30, 362-373.
29. Wege N, Dlugaj M, Siegrist J, Dragano N, Erbel R, Jockel KH, Moebus S, Weimar C. (2011) Population-based distribution and psychometric properties of a short cognitive performance measure in the population-based Heinz Nixdorf Recall study Neuroepidemiology 37, 13-20.
30. Oswald W, Fleischmann UM (1994) Nürnberger Alters- Inventar (NAI), Hogrefe Verlag für Psychologie, Göttingen.
31. Aschenbrenner S, Tucha O, Lange KW (2000) Regensburger Wortflüssigkeitstest (RWT), Hogrefe Verlag für Psychologie, Göttingen.
32. Shulman KI (2000) Clock-drawing: Is it the ideal cognitive screening test? Int J Geriatr Psychiatry 15, 548-561.
33. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M (2001) Patterns of cognitive decline in presymptomatic Alzheimer disease: A prospective community study. Arch Gen Psychiatry 58, 853-858. (Pubitemid 32979303)
34. Chen P, Ratcliff G, Belle SH, Cauley JA, DeKosky ST, Ganguli M (2000) Cognitive tests that best discriminate between presymptomatic AD and those who remain nondemented. Neurology 55, 1847-1853. (Pubitemid 32103967)
35. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC (2003) Subclassifications for mild cognitive impairment: Prevalence and predictive validity. Psychol Med 33, 1029- 1038.
36. Association AP (1994) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV, ed. 4, American Psychiatric Association, Washington.
37. Winblad B, Palmer K, Kivipelto M, Jelic V, Fratiglioni L, Wahlund LO, Nordberg A, Backman L, Albert M, Almkvist O, Arai H, Basun H, Blennow K, de Leon M, DeCarli C, Erkinjuntti T, Giacobini E, Graff C, Hardy J, Jack C, Jorm A, Ritchie K, van Duijn C, Visser P, Petersen RC (2004) Mild cognitive impairment-beyond controversies, towards a consensus: Report of the International Working Group on Mild Cognitive Impairment. J Intern Med 256, 240-246. (Pubitemid 39222993)
38. Schmermund A, Mohlenkamp S, Berenbein S, Pump H, Moebus S, Roggenbuck U, Stang A, Seibel R, Gronemeyer D, Jockel KH, Erbel R (2006) Population-based assessment of subclinical coronary atherosclerosis using electron-beam computed tomography. Atherosclerosis 185, 177-182. (Pubitemid 43117566)
39. Schmermund A, Stang A, Mohlenkamp S, Eggebrecht H, Baumgart D, Gilbert V, Gronemeyer D, Seibel R, Erbel R (2004) Prognostic value of electron-beam computed tomography-derived coronary calcium scores compared with clinical parameters in patients evaluated for coronary artery disease. Prognostic value of EBCT in symptomatic patients. Z Kardiol 93, 696-705. (Pubitemid 39304394)
40. Mohlenkamp S, Moebus S, Schmermund A, Lehmann N, Hoffmann B, Neumann T, Stang A, Dragano N, Kerkhoff G, Naber C, Kalsch H, Beck EM, Brocker-Preuss M, Kroger K, Budde T, Siegrist J, Mann K, Jockel KH, Erbel R (2007) (Assessment of the natural history of coronary artery calcification and identification of its determinants. Rationale of the 2nd part of the Heinz Nixdorf Recall Study). Herz 32, 108-120. (Pubitemid 46980391)
41. WHO (2004) The selection and use of essential medicines. World Health Organ Tech Rep Ser 920, 1-127.
42. Stang A, Moebus S, Mohlenkamp S, Dragano N, Schmermund A, Beck EM, Siegrist J, Erbel R, Jockel KH (2006) Algorithms for converting random-zero to automated oscillometric blood pressure values, and vice versa. Am J Epidemiol 164, 85-94. (Pubitemid 43946295)
43. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 289, 2560-2572. (Pubitemid 37430158)
44. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC (2007) PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81, 559-575. (Pubitemid 47330214)
45. Rosenson RS, Tangney CC, Casey LC (1999) Inhibition of proinflammatory cytokine production by pravastatin. Lancet 353, 983-984. (Pubitemid 29132615)
46. Imhof A, Woodward M, Doering A, Helbecque N, Loewel H, Amouyel P, Lowe GD, Koenig W (2004) Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: Results from three MONICA samples (Augsburg, Glasgow, Lille). Eur Heart J 25, 2092-2100. (Pubitemid 39572241)
47. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB (2000) Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses. BMJ 321, 199-204. (Pubitemid 30459555)
48. Strachan MW, Price JF, Frier BM (2008) Diabetes, cognitive impairment, and dementia. BMJ 336, 6.
49. Haan MN, Aiello AE, West NA, Jagust WJ (2008) C-reactive protein and rate of dementia in carriers and non carriers of Apolipoprotein APOE4 genotype. Neurobiol Aging 29, 1774- 1782.
50. Sauriasari R, Sakano N, Wang DH, Takaki J, Takemoto K, Wang B, Sugiyama H, Sato Y, Takigawa T, Takahashi N, Kanbara S, Hitomi Y, Nakamura H, Ogino K (2010) C-reactive protein is associated with cigarette smoking-induced hyperfiltration and proteinuria in an apparently healthy population. Hypertens Res 33, 1129-1136.
51. Hastie CE, Haw S, Pell JP (2008) Impact of smoking cessation and lifetime exposure on C-reactive protein. Nicotine Tob Res 10, 637-642. (Pubitemid 351566549)
52. O'Loughlin J, Lambert M, Karp I, McGrath J, Gray-Donald K, Barnett TA, Delvin EE, Levy E, Paradis G (2008) Association between cigarette smoking and C-reactive protein in a representative, population-based sample of adolescents. Nicotine Tob Res 10, 525-532. (Pubitemid 351385834)
53. Mohlenkamp S, Lehmann N, Moebus S, Schmermund A, Dragano N, Stang A, Siegrist J, Mann K, Jockel KH, Erbel R (2011) Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol 57, 1455-1464.
54. Wersching H, Duning T, Lohmann H, Mohammadi S, Stehling C, Fobker M, Conty M, Minnerup J, Ringelstein EB, Berger K, Deppe M, Knecht S (2010) Serum C-reactive protein is linked to cerebral microstructural integrity and cognitive function. Neurology 74, 1022-1029.
55. Hoth KF, Haley AP, Gunstad J, Paul RH, Poppas A, Jefferson AL, Tate DF, Ono M, Jerskey BA, Cohen RA (2008) Elevated C-reactive protein is related to cognitive decline in older adults with cardiovascular disease. J Am Geriatr Soc 56, 1898-1903.
56. Komulainen P, Lakka TA, Kivipelto M, Hassinen M, Penttila IM, Helkala EL, Gylling H, Nissinen A, Rauramaa R (2007) Serum high sensitivity C-reactive protein and cognitive function in elderly women. Age Ageing 36, 443-448. (Pubitemid 47261038)
57. Querfurth HW, LaFerla FM (2010) Alzheimer's disease. N Engl J Med 362, 329-344.
58. Sierra C, Coca A, Schiffrin EL (2011) Vascular mechanisms in the pathogenesis of stroke. Curr Hypertens Rep 13, 200-207.
59. Noble JM, Manly JJ, Schupf N, Tang MX, Mayeux R, Luchsinger JA (2010) Association of C-reactive protein with cognitive impairment. Arch Neurol 67, 87-92.
60. Hubacek JA, Peasey A, Pikhart H, Stavek P, Kubinova R, Marmot M, Bobak M (2010) APOE polymorphism and its effect on plasma C-reactive protein levels in a large general population sample. Hum Immunol 71, 304-308.
61. Launer LJ, Wind AW, Deeg DJ (1994) Nonresponse pattern and bias in a community-based cross-sectional study of cognitive functioning among the elderly. Am J Epidemiol 139, 803-812. (Pubitemid 24135784)
62. Blacker D, Lee H, Muzikansky A, Martin EC, Tanzi R, McArdle JJ, Moss M, Albert M (2007) Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch Neurol 64, 862-871. (Pubitemid 46919842)
63. Dickerson BC, Sperling RA, Hyman BT, Albert MS, Blacker D (2007) Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry 64, 1443-1450. (Pubitemid 350223563)